Search Result

Results for "

PPARγ Modulator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PGC-1α (1) 17β-HSD (1) Androgen Receptor (2) Apoptosis (3) Autophagy (3) Bcl-2 Family (1) Caspase (1) CaSR (1) Endogenous Metabolite (1) FABP (2) Ferroptosis (2) Glucocorticoid Receptor (1) Insulin Receptor (1) Interleukin Related (2) Isotope-Labeled Compounds (1) NF-κB (1) NO Synthase (1) PARP (3) Phosphodiesterase (PDE) (1) PPAR (39) RAR/RXR (2) Reference Standards (7) TGF-beta/Smad (1) TNF Receptor (1) TRP Channel (3) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (10) Metabolic Disease (36)

By Targets:

PGC-1α (1)

17β-HSD (1)

Androgen Receptor (2)

Apoptosis (3)

Autophagy (3)

Bcl-2 Family (1)

Caspase (1)

CaSR (1)

Endogenous Metabolite (1)

FABP (2)

Ferroptosis (2)

Glucocorticoid Receptor (1)

Insulin Receptor (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

NF-κB (1)

NO Synthase (1)

PARP (3)

Phosphodiesterase (PDE) (1)

PPAR (39)

RAR/RXR (2)

Reference Standards (7)

TGF-beta/Smad (1)

TNF Receptor (1)

TRP Channel (3)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (1)

Endocrinology (1)

Inflammation/Immunology (10)

Metabolic Disease (36)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14600

Rosiglitazone maleate Maximum Cited Publications 175 Publications Verification BRL 49653C	PPAR TRP Channel Autophagy Ferroptosis	Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of *PPARγ, with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a K_d* of appr 40 nM for *PPARγ; Rosiglitazone maleate is also an modulator* of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).

HY-100348

EPI-001	Androgen Receptor PPAR Apoptosis	Cancer
EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC₅₀ of ~6 μM. EPI-001 is also a selective modulator of *PPARγ*. EPI-001 is active against castration-resistant prostate cancer .

HY-108022A

Azemiglitazone potassium 1 Publications Verification MSDC-0602K	Insulin Receptor PPAR	Metabolic Disease
Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC₅₀ of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .

HY-128400

4'-Methoxychalcone	PARP	Metabolic Disease Cancer
4'-Methoxychalcone regulates adipocyte differentiation through *PPARγ* activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-101064S3

Fmoc-leucine-d10	PPAR	Metabolic Disease
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-100428

Netoglitazone MCC-555; Isaglitazone	PPAR	Metabolic Disease
Netoglitazone (MCC-555) is an orally active *PPARγ* ligand with an EC₅₀ of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of *PPARγ* as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus .

HY-117103

AMG131 INT131	PPAR	Metabolic Disease
AMG131 (INT131) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 binds to *PPARγ* within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 is promising for research of type-2 diabetes mellitus .

HY-12557

γ-Glutamylvaline γ-Glu-Val	Endogenous Metabolite CaSR Wnt TNF Receptor Interleukin Related PPAR β-catenin	Inflammation/Immunology
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .

HY-101064S2

Fmoc-leucine-d3 N-FMOC-leucine-d₃; NPC 15199-d₃; NSC 334290-d₃	PPAR	Metabolic Disease
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-108523

LG100754 UVI 2112	RAR/RXR	Metabolic Disease
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-101064S1

Fmoc-leucine-13C6,15N	Isotope-Labeled Compounds PPAR	Metabolic Disease
Fmoc-leucine- ¹³C₆, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity

HY-101746

GSK376501A	PPAR	Metabolic Disease
GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus .

HY-101292

FK614	PPAR	Metabolic Disease
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective *PPARγ* modulator (SPPARM). FK614 functions as a *PPARγ* agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of *PPARγ* at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .

HY-147757

PPARγ/δ modulator 1	PPAR	Metabolic Disease
PPARγ/δ modulator 1 (compound 3e) is a potent PPAR modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with K_i values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC₅₀ of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .

HY-160159

PPARγ modulator-1	PPAR	Metabolic Disease
Anticancer agent 183 (example 48) is a non-agonistic PPARG modulator. Anticancer agent 183 has a high affinity to PPARG (PPARγ). Anticancer agent 183 inhibits kinase-mediated phosphorylation of PPARG. Anticancer agent 183 can used for research on metabolic diseases to avoid side effects .

HY-173622

PPARγ modulator-4	PPAR	Metabolic Disease Endocrinology
PPARγ modulator-4 (Compound (I)) is a *PPARγ* inhibitor (K_D: 3.75 μM). PPARγ modulator-4 can inhibit CDK5-mediated phosphorylation of PPARγ at Ser245. PPARγ modulator-4 can be used in insulin resistance research .

HY-170874

PPARγ modulator-2	PPAR	Metabolic Disease
PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for *PPARγ* that inhibits PPARγ ligand-binding domain (LBD) with an IC₅₀ of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models .

HY-176062

PPARγ modulator-3	PPAR	Metabolic Disease
PPARγ modulator-3 (Compound 11) is a peroxisome proliferator-activated receptor γ (PPARγ) modulator with a K_D value of 186 nM. PPARγ modulator-3 is promising for research of insulin resistance (IR)-related diseases, such as type 2 diabetes mellitus (T2DM) and metabolic syndrome .

HY-170581

PPARγ/δ modulator 2	PPAR	Metabolic Disease
PPARγ/δ modulator 2 (Compound 3h) is a *PPARγ* agonist and PPARδ antagonist. The K_i values for *PPARγ* and PPARδ are 2.8 μM and 43 nM, respectively. PPARγ/δ modulator 2 significantly enhances the production of Adiponectin and promotes adipogenic differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs). PPARγ/δ modulator 2 can be used in the study of metabolic disorders associated with hypoadiponectinemia .

HY-151963

PPARγ/GR modulator 1	PPAR Glucocorticoid Receptor	Metabolic Disease
PPARγ/GR modulator 1 is an orally active dual agonist of *PPARγ* and glucocorticoid receptor (GR), with K_is of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes .

HY-108572

S26948	PPAR	Cardiovascular Disease Metabolic Disease
S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC₅₀=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ .

HY-163432

YGL-12	PPAR	Metabolic Disease
YGL-12 is a potent *PPARγ* modulator with good binding affinity and an IC₅₀ value of 0.85 μM. YGL-12 effectively blocks PPARγ Ser273 phosphorylation and can be used in diabetes research .

HY-B0700

Rosiglitazone sodium BRL 49653 sodium	PPAR TRP Channel Autophagy	Metabolic Disease Inflammation/Immunology
Rosiglitazone sodium is a potent and selective activator of *PPARγ, with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a K_d* of appr 40 nM for *PPARγ; Rosiglitazone sodium is also an modulator* of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).

HY-14600R

Rosiglitazone maleate (Standard) BRL 49653C (Standard)	Reference Standards PPAR TRP Channel Autophagy Ferroptosis	Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (maleate) (Standard) is the analytical standard of Rosiglitazone (maleate). This product is intended for research and analytical applications. Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of *PPARγ, with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a K_d* of appr 40 nM for *PPARγ; Rosiglitazone maleate is also an modulator* of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).

HY-118397

RB394	PPAR	Others
RB394 is a potent dual sEH/PPARγ modulator isoform that promotes adipocyte browning and exhibits cardioprotective activity, and can be used to suppress metabolic syndrome.

HY-126969

C333H	PPAR	Metabolic Disease
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .

HY-147705

PPARγ phosphorylation inhibitor 1	PPAR	Metabolic Disease
PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC₅₀ of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC₅₀ of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects .

HY-W109107

GED 0507-34-Levo	PPAR TGF-beta/Smad Interleukin Related	Inflammation/Immunology
GED 0507-34-Levo is an orally active *PPARγ* modulator. GED 0507-34-Levo downregulates the expression of TGF-β, Smad3, IL-13, and CTGF in the colon. GED 0507-34-Levo improves DSS-induced chronic colitis and fibrosis .

HY-128400R

4'-Methoxychalcone (Standard)	PARP Reference Standards	Metabolic Disease Cancer
4'-Methoxychalcone (Standard) is the analytical standard of 4'-Methoxychalcone. This product is intended for research and analytical applications. 4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-100428R

Netoglitazone (Standard) MCC-555 (Standard); Isaglitazone (Standard)	Reference Standards PPAR	Metabolic Disease
Netoglitazone (Standard) is the analytical standard of Netoglitazone (HY-100428). This product is intended for research and analytical applications. Netoglitazone (MCC-555) is an orally active *PPARγ* ligand with an EC₅₀ of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of *PPARγ* as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus .

HY-172883

*ABP/PPAR* modulator 1**	FABP PPAR	Metabolic Disease Inflammation/Immunology
ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-172883A

*(E/Z)-ABP/PPAR* modulator 1**	FABP PPAR	Metabolic Disease Inflammation/Immunology
(E/Z)-ABP/PPAR modulator 1 is a mixture of the E and Z isomers of ABP/PPAR modulator 1 (HY-172883). ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-117103A

AMG131 benzenesulfonate INT131 benzenesulfonate	PPAR	Metabolic Disease
AMG131 (INT131) (benzenesulfonate) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 (benzenesulfonate) binds to *PPARγ* within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 (benzenesulfonate) is promising for research of type-2 diabetes mellitus .

HY-179015

*HSD17B13/PPAR* modulator-1**	17β-HSD PPAR	Metabolic Disease Inflammation/Immunology
HSD17B13/PPAR modulator-1 (Compound 17) is a HSD17B13/PPAR multitarget modulator. HSD17B13/PPAR modulator-1 is an inhibitor of HSD17B13, with its IC₅₀ value being 0.91 μM. HSD17B13/PPAR modulator-1 is a PPAR agonist, with the EC₅₀ values for PPARα, PPARδ, and PPARγ being 1.55, 0.12, and 0.01 μM respectively. HSD17B13/PPAR modulator-1 can significantly improve liver function, regulate lipid metabolism, alleviate fibrosis, and exert antioxidant and anti-inflammatory effects in the model of metabolic dysfunction-related steatohepatitis (MASH). HSD17B13/PPAR modulator-1 can be used for the study of MASH .

HY-161926

YGT-31	PPAR	Metabolic Disease
YGT-31 is a modulator for *PPARγ* with an IC₅₀ of 1.72 μM, and a K_i of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .

HY-100348R

EPI-001 (Standard)	Reference Standards Androgen Receptor PPAR Apoptosis	Cancer
EPI-001 (Standard) is the analytical standard of EPI-001. This product is intended for research and analytical applications. EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC₅₀ of ~6 μM. EPI-001 is also a selective modulator of *PPARγ*. EPI-001 is active against castration-resistant prostate cancer .

HY-116115

17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid 17-Oxo-DPA; 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-DPA	NF-κB PPAR	Inflammation/Immunology
17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid (17-Oxo-DPA; 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-DPA) is an electrophilic oxo-derivative (EFOX) of the docosahexaenoic acid (DHA) (HY-B2167). 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid is generated during inflammation by COX-2-catalyzed mechanism in activated macrophages. 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid acts as an agonist for *PPARγ* and a modulator for NF-κB signaling pathway, inhibits the production of pro-inflammatory cytokines and nitric oxide, and exhibits anti-inflammatory efficacy .

HY-101292R

FK614 (Standard)	PPAR Reference Standards	Metabolic Disease
FK614 (Standard) is the analytical standard of FK614 (HY-101292). This product is intended for research and analytical applications. FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .

HY-101064R

Fmoc-leucine (Standard) N-FMOC-leucine (Standard); NPC 15199 (Standard); NSC 334290 (Standard)	PPAR Reference Standards	Metabolic Disease
Fmoc-leucine (Standard) is the analytical standard of Fmoc-leucine (HY-101064). This product is intended for research and analytical applications. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-180398

PA-082	PPAR PGC-1α	Metabolic Disease
PA-082 is a selective *PPAR-γ* modulator that functions as a partial agonist. PA-082 causes partial recruitment of SRC1, TIF2, SRC3 and full recruitment of PGC1-α to PPAR-γ ligand-binding domain. PA-082 prevents triglyceride accumulation during de novo adipogenesis and antagonizes Rosiglitazone (HY-17386)-induced lipid accumulation. PA-082 potentiates insulin-stimulated glucose uptake in adipocytes and protects against TNFα-induced insulin resistance. PA-082 can be used for the research of type 2 diabetes .

HY-108523R

LG100754 (Standard) UVI 2112 (Standard)	Reference Standards RAR/RXR	Metabolic Disease
LG100754 (Standard) is the analytical standard of LG100754 (HY-108523). This product is intended for research and analytical applications. LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-122222

MRL20	PPAR	Others
MRL20 is a PPARγ constitutive and allosteric agonist. MRL20 enhances the interaction between PPARγ and the co-activating peptide of TRAP220, with its EC₅₀ being 10 nM. Even after being covalently blocked in the constitutive pocket by GW9662 (HY-16578) or T0070907 (HY-13202), MRL20 can still strengthen the interaction between PPARγ and TRAP220, with EC₅₀ values of 176 and 440 nM respectively. MRL20 fails to completely inhibit its cell activation effect. MRL20 can be used to study the allosteric regulatory mechanism of PPARγ .

HY-N17617

S-Petasin	Phosphodiesterase (PDE) Apoptosis NO Synthase Caspase PPAR Bcl-2 Family PARP	Metabolic Disease Inflammation/Immunology Cancer
S-Petasin is a phosphodiesterase (PDE) inhibitor with IC₅₀ values of 25.5 μM and 17.5 μM for PDE3 and PDE4, respectively. S-Petasin inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, *PPAR-γ, and iNOS* induction at RNA and protein levels. S-Petasin induces apoptosis, activates caspases, cleaves PARP, modulates mitochondrial membrane permeability, and regulates BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, CDK4, and cyclin D1 expression. S-Petasin reduces inflammatory cell accumulation, cytokine and IgE levels, and enhances serum IgG2a levels. S-Petasin relaxes isolated sensitized guinea pig trachealis and exhibits gastrointestinal anti-spasmodic activity. S-Petasin reduces tonsillitis severity and asthmatic attack frequency. S-Petasin can be used for the research of prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis .

Cat. No.	Product Name	Target	Research Area